New IDegLira data show glycaemic improvements in type 2 diabetes

New analyses of Phase 3a IDegLira (insulin degludec /liraglutide; Xultophy®) DUALTM study data show an early and substantial improvement in glycaemic control, and a beneficial weight profile in type 2 diabetes patients compared to insulin degludec.

Source: Pharmacy Europe - September 19, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Diabetes blood glucose targets diabetes type 2 insulin degludec/liraglutide Latest News Source Type: news